Decreased level of serum autoantibody against LG72 is a biosignature of amyotrophic lateral sclerosis

Biomark Med. 2016;10(1):73-9. doi: 10.2217/bmm.15.80.

Abstract

Aim: LG72 can increase mitochondrial ROSs and oxidative stress has been implicated in the pathophysiology of amyotrophic lateral sclerosis (ALS). The serum level of LG72 or LG72-related molecules might therefore be associated with ALS. Here, we aim to determine the serum autoantibody against LG72 has potential as a biomarker for the diagnosis of ALS.

Materials: Seventy-eighty patients with ALS, 45 patients with AD, 43 patients with PD and 88 healthy adults were enrolled.

Results: The concentration of serum autoantibody against LG72 was more than fourfold lower in ALS than other control groups (p < 0.001). The AUC was 0.9627 when the cut-off value for autoantibody concentration was 0.167 μg/ml.

Conclusion: This finding suggests that the autoantibody against LG72 might serve as a surrogate biomarker for ALS.

Keywords: LG72; amyotrophic lateral sclerosis; autoantibody.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Amyotrophic Lateral Sclerosis / blood*
  • Amyotrophic Lateral Sclerosis / diagnosis
  • Amyotrophic Lateral Sclerosis / immunology*
  • Autoantibodies / blood*
  • Autoantibodies / immunology*
  • Biomarkers / blood
  • Carrier Proteins / immunology*
  • Case-Control Studies
  • Female
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Male
  • Middle Aged

Substances

  • Autoantibodies
  • Biomarkers
  • Carrier Proteins
  • DAOA protein, human
  • Intracellular Signaling Peptides and Proteins